Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F17%3A10374481" target="_blank" >RIV/00216208:11130/17:10374481 - isvavai.cz</a>

Alternative codes found

RIV/00064203:_____/17:10374481

Result on the web

<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240256/" target="_blank" >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240256/</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/s12882-017-0444-6" target="_blank" >10.1186/s12882-017-0444-6</a>

Result language

angličtina

Original language name

Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial

Original language description

Background: Preclinical studies demonstrate renal proximal tubular injury after administration of some intravenous iron preparations but clinical data on renal effects of intravenous iron are sparse. Methods: FIND-CKD was a 56-week, randomized, open-label, multicenter study in which patients with non-dialysis dependent chronic kidney disease (ND-CKD), anemia and iron deficiency without erythropoiesis-stimulating agent therapy received intravenous ferric carboxymaltose (FCM), targeting either higher (400-600 mu g/L) or lower (100-200 mu g/L) ferritin values, or oral iron. Results: Mean (SD) eGFR at baseline was 34.9 (11.3), 32.8 (10.8) and 34.2 (12.3) mL/min/1.73 m(2) in the high ferritin FCM (n = 97), low ferritin FCM (n = 89) and oral iron (n = 167) groups, respectively. Corresponding values at month 12 were 35.6 (13.8), 32.1 (12.7) and 33.4 (14.5) mL/min/1.73 m(2). The pre-specified endpoint of mean (SE) change in eGFR from baseline to month 12 was +0.7 (0.9) mL/min/1.73 m(2) with high ferritin FCM (p = 0.15 versus oral iron), -0.9 (0.9) mL/min/1.73 m(2) with low ferritin FCM (p = 0.99 versus oral iron) and -0.9 (0.7) mL/min/1.73 m(2) with oral iron. No significant association was detected between quartiles of FCM dose, change in ferritin or change in TSAT versus change in eGFR. Dialysis initiation was similar between groups. Renal adverse events were rare, with no indication of between-group differences. Conclusion: Intravenous FCM at doses that maintained ferritin levels of 100-200 mu g/L or 400-600 mu g/L did not negatively impact renal function (eGFR) in patients with ND-CKD over 12 months versus oral iron, and eGFR remained stable. These findings show no evidence of renal toxicity following intravenous FCM over a 1-year period.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30217 - Urology and nephrology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

BMC Nephrology

ISSN

1471-2369

e-ISSN

—

Volume of the periodical

18

Issue of the periodical within the volume

Januar

Country of publishing house

GB - UNITED KINGDOM

Number of pages

18

Pages from-to

—

UT code for WoS article

000393075200001

EID of the result in the Scopus database

2-s2.0-85011263121